Baricitinib Safety and Monitoring
Introduction to Baricitinib Safety
- Baricitinib is associated with several significant side effects, including increased risk of infections, thromboembolism, laboratory abnormalities, and gastrointestinal perforations, requiring careful patient selection and monitoring during treatment, as recommended by the European Medicines Agency 1, 2
Infections
- Upper respiratory tract infections are among the most common adverse events 1
- Opportunistic infections, including herpes simplex, herpes zoster, and tuberculosis, have been reported 1
- The American College of Rheumatology recommends vaccinating patients against herpes zoster before starting treatment if possible 1
Laboratory Abnormalities
- Lymphopenia and neutropenia may occur, with the American College of Rheumatology recommending dose reduction or temporary cessation for absolute neutrophil count <1000/mm³ or absolute lymphocyte count <750/mm³ 2
- Creatinine phosphokinase (CPK) elevations, occasionally with myalgia, have been reported 2
- Creatinine increases without organ dysfunction have been observed 2
- Lipid elevations (LDL cholesterol) have been reported, with the European Society of Cardiology recommending regular lipid level monitoring 2
- Liver enzyme elevations have been reported 1
Thromboembolism
- Venous thromboembolism (VTE) risk is increased, particularly with the 4 mg dose, with the European Medicines Agency updating the baricitinib label with a warning for patients at risk of thromboembolic disease 2, 3
- Risk factors include age >65, obesity, history of VTE, and use of Cox-2 inhibitors, with the American Heart Association recommending careful patient selection and monitoring 2
Gastrointestinal Perforations
- Gastrointestinal perforations have been reported in clinical trials with baricitinib, with higher risk in patients with history of diverticulitis and those taking concomitant NSAIDs or glucocorticoids 2
- The American Gastroenterological Association recommends careful patient selection and monitoring for patients with history of diverticulitis 2
Monitoring and Patient Selection
- The American College of Rheumatology recommends complete blood count with differential, liver function tests, renal function assessment, lipid profile, tuberculosis screening, hepatitis B and C testing, and VTE risk assessment before starting treatment 2, 4
- Regular monitoring of blood count and differential, transaminases, renal function, and lipid levels is recommended during treatment, with the European League Against Rheumatism recommending dose reduction or temporary cessation for laboratory parameters requiring action 2
- Patients at higher risk for complications, including elderly patients, patients with history of VTE, patients with cardiovascular risk factors, and those with history of diverticulitis, require careful monitoring and dose adjustment, as recommended by the American Geriatrics Society 2
- The American College of Obstetricians and Gynecologists recommends avoiding use in women contemplating pregnancy due to limited safety data 4